ONC Nurse (cn.com/home CME Information)

Article

Integrating Genetics and Genomics Into Oncology Nursing March 1, 2010 By Dale Halsey Lea, MPH, RN, CGC, FAAN Health Educator, National Human Genome Research Institute

Integrating Genetics and Genomics Into Oncology Nursing
March 1, 2010
By Dale Halsey Lea, MPH, RN, CGC, FAAN
Health Educator, National Human Genome Research Institute


This activity is based on articles and reports in ONCOLOGY Nurse Edition. It is developed from an identified educational need for information about practical management issues in medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.
 

CME, 1.0 Credits
Hosted on cmellc.com

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
4 experts in this video
2 experts in this video
Related Content
Nurulimab/Prolgolimab Yield Superior Efficacy in Advanced Melanoma

Nurulimab/Prolgolimab Yield Superior Efficacy in Advanced Melanoma

Ariana Pelosci
April 28th 2025
Article

The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

Same-Day G-CSF After Chemo Appears Safe, Efficacious in Breast Cancer

Roman Fabbricatore
April 28th 2025
Article

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

Tim Cortese
April 28th 2025
Article
Radical Prostatectomy Linked to Lower GU Toxicity in Localized Prostate Cancer

Radical Prostatectomy Linked to Lower GU Toxicity in Localized Prostate Cancer

Ariana Pelosci
April 28th 2025
Article

Toxicity complications were assessed between single- and multiple-treatment modalities for patients with localized prostate cancer.